Combining de novo molecular design with semiempirical protein-ligand binding free energy calculation

Semi-empirical quantum chemistry methods estimate the binding free energies of protein-ligand complexes. We present an integrated approach combining the GFN2- TB method with design for the generation and evaluation of potential inhibitors of acetylcholinesterase (AChE). We employed chemical language...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RSC advances 2024-11, Vol.14 (50), p.37035-37044
Hauptverfasser: Iff, Michael, Atz, Kenneth, Isert, Clemens, Pachon-Angona, Irene, Cotos, Leandro, Hilleke, Mattis, Hiss, Jan A, Schneider, Gisbert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Semi-empirical quantum chemistry methods estimate the binding free energies of protein-ligand complexes. We present an integrated approach combining the GFN2- TB method with design for the generation and evaluation of potential inhibitors of acetylcholinesterase (AChE). We employed chemical language model-based molecule generation to explore the synthetically accessible chemical space around the natural product Huperzine A, a potent AChE inhibitor. Four distinct molecular libraries were created using structure- and ligand-based molecular design with SMILES and SELFIES representations, respectively. These libraries were computationally evaluated for synthesizability, novelty, and predicted biological activity. The candidate molecules were subjected to molecular docking to identify hypothetical binding poses, which were further refined using Gibbs free energy calculations. The structurally novel top-ranked molecule was chemically synthesized and biologically tested, demonstrating moderate micromolar activity against AChE. Our findings highlight the potential and certain limitations of integrating deep learning-based molecular generation with semi-empirical quantum chemistry-based activity prediction for structure-based drug design.
ISSN:2046-2069
2046-2069
DOI:10.1039/d4ra05422a